报价延迟最少15分钟:2026/11/05 05:45 EST
盘前时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.6
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.32/1.08
|
|
企业价值
12.20B
|
| 资产负债 |
|
每股账面净值
18.01
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
5.10B
|
|
每股收益
11.10
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications. |
